{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-219395","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2026-05-12T20:07:19+00:00","discovered_at":"2026-05-12T20:08:00.302384+00:00","generated_at":"2026-05-12T21:25:42.116039+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Verrica Q1 2026: Net revenue $5.0M; YCANTH units up 51% YoY; net loss $9.7M","bullets":["YCANTH dispensed units 15,302 (+12.1% QoQ, +51.3% YoY); net product revenue $4.3M (+16.2% QoQ, +25.4% YoY).","Total revenue $5.0M includes $0.7M license/collaboration revenue from Torii Japan launch.","Net loss $9.7M ($0.45 per share); non-GAAP net loss $8.8M ($0.41 per share).","Phase 3 common warts trial (COVE-2) >50% enrolled; second trial (COVE-3) expected mid-2026.","Appointed Chris Chapman as Chief Commercial Officer; Phase 2 VP-315 BCC data to be presented at SID May 13-16."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-219395","json":"https://secwatch.observer/filing/0001193125-26-219395.json","markdown":"https://secwatch.observer/filing/0001193125-26-219395.md","text":"https://secwatch.observer/filing/0001193125-26-219395.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312526219395/0001193125-26-219395-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312526219395/d152529d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T21:25:42.116039+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}